Allstate Corp acquired a new stake in shares of Kenvue Inc. (NYSE:KVUE - Free Report) in the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The fund acquired 57,503 shares of the company's stock, valued at approximately $1,228,000.
Several other hedge funds and other institutional investors have also recently modified their holdings of the stock. DnB Asset Management AS grew its stake in shares of Kenvue by 6.3% during the 4th quarter. DnB Asset Management AS now owns 381,232 shares of the company's stock valued at $8,139,000 after acquiring an additional 22,590 shares during the period. Alerus Financial NA increased its stake in shares of Kenvue by 50.6% in the fourth quarter. Alerus Financial NA now owns 288,088 shares of the company's stock worth $6,151,000 after purchasing an additional 96,743 shares in the last quarter. Orion Portfolio Solutions LLC raised its position in shares of Kenvue by 1.9% during the 4th quarter. Orion Portfolio Solutions LLC now owns 206,747 shares of the company's stock valued at $4,414,000 after purchasing an additional 3,936 shares during the period. Providence Capital Advisors LLC purchased a new position in shares of Kenvue during the 4th quarter valued at $2,557,000. Finally, Norges Bank purchased a new position in shares of Kenvue during the 4th quarter valued at $521,348,000. 97.64% of the stock is currently owned by hedge funds and other institutional investors.
Kenvue Trading Down 5.5 %
Shares of NYSE:KVUE traded down $1.29 during trading on Friday, reaching $22.33. The company's stock had a trading volume of 17,763,957 shares, compared to its average volume of 16,790,135. The firm's 50 day simple moving average is $22.59 and its two-hundred day simple moving average is $22.47. The company has a current ratio of 1.00, a quick ratio of 0.69 and a debt-to-equity ratio of 0.66. Kenvue Inc. has a 12 month low of $17.67 and a 12 month high of $24.46. The stock has a market capitalization of $42.68 billion, a PE ratio of 42.14, a price-to-earnings-growth ratio of 2.62 and a beta of 1.25.
Kenvue (NYSE:KVUE - Get Free Report) last announced its earnings results on Thursday, February 6th. The company reported $0.26 EPS for the quarter, hitting analysts' consensus estimates of $0.26. Kenvue had a return on equity of 20.97% and a net margin of 6.66%. On average, research analysts predict that Kenvue Inc. will post 1.14 EPS for the current fiscal year.
Kenvue Dividend Announcement
The company also recently declared a quarterly dividend, which was paid on Wednesday, February 26th. Investors of record on Wednesday, February 12th were paid a dividend of $0.205 per share. The ex-dividend date was Wednesday, February 12th. This represents a $0.82 dividend on an annualized basis and a dividend yield of 3.67%. Kenvue's dividend payout ratio is presently 154.72%.
Wall Street Analyst Weigh In
A number of equities research analysts have commented on the company. Evercore ISI assumed coverage on Kenvue in a report on Monday, March 24th. They set an "in-line" rating and a $25.00 price target on the stock. Barclays lifted their target price on Kenvue from $21.00 to $23.00 and gave the company an "equal weight" rating in a research note on Thursday, March 27th. Royal Bank of Canada restated a "sector perform" rating and issued a $24.00 price target on shares of Kenvue in a research note on Monday, February 3rd. Deutsche Bank Aktiengesellschaft cut shares of Kenvue from a "buy" rating to a "hold" rating and reduced their price objective for the company from $25.00 to $24.00 in a research report on Thursday, December 12th. Finally, Canaccord Genuity Group upped their target price on shares of Kenvue from $24.00 to $29.00 and gave the stock a "buy" rating in a research report on Wednesday, March 5th. One equities research analyst has rated the stock with a sell rating, seven have given a hold rating and five have issued a buy rating to the company's stock. According to MarketBeat.com, Kenvue presently has an average rating of "Hold" and a consensus price target of $24.00.
Get Our Latest Stock Report on KVUE
Kenvue Company Profile
(
Free Report)
Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.
Further Reading
Before you consider Kenvue, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Kenvue wasn't on the list.
While Kenvue currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know? MarketBeat just compiled its list of the twelve stocks that corporate insiders are abandoning. Complete the form below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
